Play of chance versus concerns regarding dipeptidyl peptidase-4 inhibitors: Heart failure and diabetes

Clinical Diabetes

Volumn 32, Issue 3, 2014, Pages 121-126

  Sanon, Vani P ^a   Sanon, Saurabh ^b   Pham, Son V ^c   Chilton, Robert ^a,c  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b MAYO CLINIC   (United States)

^c Spinal Cord Injury Service Audie L Murphy Veteran's Administration Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84904390661     PISSN: 08918929     EISSN: None     Source Type: Journal    
DOI: 10.2337/diaclin.32.3.121     Document Type: Note

References (14)

1. McMurray JJ: Clinical practice: systolic heart failure. N Engl J Med 362:228-238, 2010
2. McMurray JJ, Pfeffer MA: Heart failure. Lancet 365:1877-1889, 2005
3. Qiang L, Hong L, Ningfu W, Huaihong C, Jing W: Expression of miR-126 and miR-508-5p in endothelial progenitor cells is associated with the prognosis of chronic heart failure patients. Int J Cardiol 168:2082-2088, 2013
4. Wang HW, Huang TS, Lo HH, Huang PH: Deficiency of the microRNA-31-microRNA-720 pathway in the plasma and endothelial progenitor cells from patients with coronary artery disease. Arterioscler Thromb Vasc Biol 34:857-869, 2014
5. Dandamudi S, Slusser J, Mahoney DW, Redfield MM, Rodeheffer RJ, Chen HH: The prevalence of diabetic cardiomyopathy: a population based study in Olmsted County, MN. J Card Fail. Electronically published ahead of print on 24 February 2014 (doi: 10.1016/j.cardfail.2014.02.007)
6. Juhaeri J, Gao S, Dai WS: Incidence rates of heart failure, stroke, and acute myocardial infarction among type 2 diabetic patients using insulin glargine and other insulin. Pharmacoepidemiol Drug Saf 18:497-503, 2009
7. Bertoni AG, Hundley WG, Massing MW, Bonds DE, Burke GL, Goff DC Jr: Heart failure prevalence, incidence, and mortality in the elderly with diabetes. Diabetes Care 27:699-703, 2004
8. Cerhan JR, Moore SC, Jacobs EJ: A pooled analysis of waist circumference and mortality in 650,000 adults. Mayo Clin Proc 89:335-345, 2014
9. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P, Frederich R, Wiviott SD, Hoffman EB, Cavender MA, Udell JA, Desai NR, Mosenzon O, McGuire DK, Ray KK, Leiter LA, Raz I, for the SAVOR-TIMI 53 Steering Committee and Investigators: Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 369:1317-1326, 2013
10. White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, Perez AT, Fleck PR, Mehta CR, Kupfer S, Wilson C, Cushman WC, Zannad F, for the EXAMINE Investigators: Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 369:1327-1335, 2013
11. Bhatt DL, on behalf of the SAVORTIMI 53 Steering Committee and Investigators: Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus (SAVOR)-TIMI 53. Presentation delivered at the European Association for the Study of Diabetes 49th annual meeting on 26 September 2013 in Barcelona, Spain
12. Sitagliptin cardiovascular outcome study (MK-0431-082) (TECOS). Available from http://clinicaltrials.gov/ct2/show/NCT 00790205?term=NCT00790205&rank=1. Accessed 15 April 2014
13. CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimeperide in Patients with Type 2 Diabetes. Available from http://clinicaltrials.gov/ct2/show/NCT012434 24?term=NCT01243424&rank=1. Accessed 15 April 2014
14. Evanson KW, Stone AJ, Hammond AL, Kluess HA: Neuropeptide Y overflow and metabolism in skeletal muscle arterioles. J Physiol 589:3309-3318, 2011